A phase I trial involving nivolumab and ipilimumab, with or without the live bacterial supplement CBM588 (bacterium spp Clostridium butyricum), showed a trend toward improved outcomes.
← all excerpts
Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
1
—
—